Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
N MuraliMurali Ramanathan

Abstract

Cholesterol is an important structural component of myelin and essential for brain homeostasis. Our objective was to investigate whether longitudinal changes in cholesterol biomarkers are associated with neurodegeneration in multiple sclerosis (MS). This prospective, longitudinal study (n = 154) included 41 healthy controls, 76 relapsing-remitting MS subjects and 37 progressive MS subjects. Neurological examination, brain magnetic resonance imaging and blood samples were obtained at baseline and at 5-year follow-up visits. Cholesterol biomarkers measured included plasma total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol and the apolipoproteins ApoA-I, Apo-II, ApoB, ApoC-II and ApoE. Key cholesterol pathway single nucleotide polymorphisms were genotyped. Greater percentage increases in HDL-C and ApoA-I levels were associated with a lower rate of gray matter and cortical volume loss. Greater percentage increases in low-density lipoprotein cholesterol were associated with increases in new T2 lesions. The percentage increases in HDL-C (P = 0.032) and ApoA-I (P = 0.007) were smaller in patients with relapsing-remitting MS at baseline who converted to secondary progressive MS during t...Continue Reading

References

Jul 24, 2010·Nature Chemistry·Michael D Ward
Oct 6, 2011·Journal of Neuroinflammation·Bianca Weinstock-GuttmanMurali Ramanathan
May 1, 2012·Annual Review of Nutrition·Hong Wang, Robert H Eckel
Jan 29, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Richard W BrowneMurali Ramanathan
May 16, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Prudence TetteyIngrid van der Mei
May 30, 2014·Neurology·Fred D LublinChris H Polman
Aug 19, 2014·Neurobiology of Disease·David A HottmanLing Li
Aug 6, 2015·Journal of Lipid Research·Kelly FellowsMurali Ramanathan
Feb 10, 2016·Multiple Sclerosis and Related Disorders·Simon ZhornitskyManu Rangachari
Feb 21, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Yan ZhangUNKNOWN Ausimmune/AusLong Investigators Group

❮ Previous
Next ❯

Citations

Dec 31, 2020·Antioxidants·Cadiele Oliana ReichertSergio P Bydlowski
Jul 20, 2020·Multiple Sclerosis and Related Disorders·Mason McCombMurali Ramanathan
May 1, 2021·Frontiers in Endocrinology·Inés Pineda-TorraElizabeth C Jury
Jul 25, 2021·International Journal of Molecular Sciences·Maria PodbielskaAnna Pokryszko-Dragan

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.